Award
National Institute on Drug Abuse 1U01DA057846-01
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
Recipient
Virginia Commonwealth University
Award Amount
$1,597,923.00
Ceiling
$1,597,923.00
Awarded
September 20, 2022
Identifier
1U01DA057846-01
A clinical trial funded by NIDA to test transdermal rotigotine as an adjunct to behavioral therapy for cocaine use disorder, aiming to improve abstinence and executive function through personalized treatment.
Description
This project proposes a clinical trial of transdermal rotigotine (RTG), a dopamine receptor agonist, as an adjunct to cognitive behavioral therapy (CBT) to improve cocaine abstinence and executive function (EF). The trial will compare outcomes between participants receiving RTG and placebo, assessing brain activation via fMRI and neurocognitive performance. The goal is to determine if RTG enhances brain function and behavior, especially in individuals with poor baseline EF, moving toward personalized treatment approaches.